Anixa Biosciences (ANIX) News Today $3.21 -0.15 (-4.46%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 6 at 11:32 AM | msn.comResearchers developing vaccine that could possibly prevent breast cancerSeptember 3, 2024 | prnewswire.comAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research SymposiumAugust 26, 2024 | prnewswire.comAnixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceAugust 9, 2024 | uk.investing.comEF Hutton sets stock target on Anixa Biosciences sharesAugust 8, 2024 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Upgraded to "Strong-Buy" at EF Hutton Acquisition Co. IEF Hutton Acquisition Co. I raised Anixa Biosciences to a "strong-buy" rating in a research note on Wednesday.August 7, 2024 | msn.comEF Hutton Initiates Coverage of Anixa Biosciences (ANIX) with Buy RecommendationAugust 2, 2024 | insidertrades.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases 21,646 Shares of StockAugust 1, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Acquires 21,646 SharesAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 21,646 shares of the company's stock in a transaction that occurred on Tuesday, July 30th. The stock was acquired at an average price of $3.06 per share, with a total value of $66,236.76. Following the acquisition, the director now owns 890,754 shares in the company, valued at $2,725,707.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.July 29, 2024 | msn.comAnixa Biosciences And 3 Other Stocks Under $5 Insiders Are BuyingJuly 29, 2024 | prnewswire.comAnixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual MeetingJuly 28, 2024 | investing.comAnixa Biosciences director buys $15,450 worth of sharesJuly 27, 2024 | insidertrades.comArnold M. Baskies Acquires 5,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockJuly 26, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $15,450.00 in StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies bought 5,000 shares of the firm's stock in a transaction on Friday, July 26th. The stock was acquired at an average cost of $3.09 per share, with a total value of $15,450.00. Following the completion of the purchase, the director now owns 115,000 shares of the company's stock, valued at approximately $355,350. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.July 26, 2024 | finance.yahoo.comWe're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash WiselyJuly 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Anixa Biosciences Amid Promising Cancer Therapy TrialsJuly 24, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Anixa Biosciences (NASDAQ:ANIX)HC Wainwright reiterated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Wednesday.July 23, 2024 | msn.comCW39 New Breast Cancer Vaccine undergoing clinical TrialsJuly 23, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T TherapyJuly 23, 2024 | uk.finance.yahoo.comEXCLUSIVE: FDA Approves Anixa Biosciences' Individual Patient Trial Application For Ovarian Cancer CAR-T TherapyJuly 23, 2024 | prnewswire.comAnixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T TherapyJuly 17, 2024 | prnewswire.comAnixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine TechnologyJuly 15, 2024 | prnewswire.comAnixa Biosciences Announces $5 Million Share Repurchase ProgramJune 24, 2024 | prnewswire.comAnixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical TrialJune 11, 2024 | insidertrades.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases 10,738 Shares of StockJune 10, 2024 | marketbeat.comLewis H. Titterton, Jr. Acquires 10,738 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. bought 10,738 shares of the company's stock in a transaction on Friday, June 7th. The shares were acquired at an average price of $2.52 per share, with a total value of $27,059.76. Following the transaction, the director now directly owns 848,775 shares of the company's stock, valued at $2,138,913. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.June 10, 2024 | marketbeat.comHC Wainwright Trims Anixa Biosciences (NASDAQ:ANIX) Target Price to $7.00HC Wainwright dropped their price target on Anixa Biosciences from $12.00 to $7.00 and set a "buy" rating for the company in a report on Monday.June 8, 2024 | insidertrades.comInsider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Acquires 6,250 Shares of StockJune 7, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani Purchases 6,250 SharesAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) CFO Michael Catelani bought 6,250 shares of the firm's stock in a transaction that occurred on Friday, June 7th. The stock was purchased at an average price of $2.40 per share, with a total value of $15,000.00. Following the completion of the purchase, the chief financial officer now owns 35,211 shares in the company, valued at $84,506.40. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.June 7, 2024 | marketbeat.comAnixa Biosciences (NASDAQ:ANIX) Announces Quarterly Earnings ResultsAnixa Biosciences (NASDAQ:ANIX - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01.June 1, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Down 12.3% in MayAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) was the target of a large decrease in short interest in May. As of May 15th, there was short interest totalling 554,300 shares, a decrease of 12.3% from the April 30th total of 632,100 shares. Currently, 1.8% of the shares of the company are sold short. Based on an average daily volume of 111,000 shares, the short-interest ratio is presently 5.0 days.May 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentMay 21, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical TrialMay 21, 2024 | prnewswire.comAnixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical TrialMay 8, 2024 | finanznachrichten.deAnixa Biosciences, Inc.: Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer VaccinesMay 8, 2024 | msn.comAnixa Biosciences enters JV with Cleveland Clinic for additional cancer vaccinesMay 8, 2024 | markets.businessinsider.comAnixa Inks Joint Development Agreement With Cleveland Clinic To Develop Novel Cancer VaccinesMay 8, 2024 | prnewswire.comAnixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer VaccinesMay 6, 2024 | prnewswire.comAnixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay JunejaApril 30, 2024 | prnewswire.comAnixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024April 18, 2024 | finance.yahoo.comAnixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory BoardApril 11, 2024 | insidertrades.comLewis H. Titterton, Jr. Acquires 15,009 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) StockApril 10, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. Buys 15,009 SharesAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Lewis H. Titterton, Jr. acquired 15,009 shares of the firm's stock in a transaction dated Tuesday, April 9th. The stock was purchased at an average cost of $3.28 per share, with a total value of $49,229.52. Following the transaction, the director now owns 838,037 shares in the company, valued at $2,748,761.36. The purchase was disclosed in a legal filing with the SEC, which is available at this link.March 22, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) to Post Q1 2025 Earnings of ($0.11) Per Share, HC Wainwright ForecastsAnixa Biosciences, Inc. (NASDAQ:ANIX - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Anixa Biosciences in a report issued on Thursday, March 21st. HC Wainwright analyst Y. Chen anticipates that the company will post earnings of ($0.1March 21, 2024 | marketbeat.comAnixa Biosciences' (ANIX) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $12.00 price target on shares of Anixa Biosciences in a research report on Thursday.March 18, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Short Interest Up 8.2% in FebruaryAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) saw a large growth in short interest in the month of February. As of February 29th, there was short interest totalling 618,200 shares, a growth of 8.2% from the February 14th total of 571,500 shares. Approximately 2.1% of the shares of the company are short sold. Based on an average trading volume of 211,200 shares, the days-to-cover ratio is currently 2.9 days.March 16, 2024 | finance.yahoo.comANIX Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comANIX Apr 2024 2.500 putMarch 16, 2024 | insidertrades.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Buys $36,300.00 in StockMarch 15, 2024 | marketbeat.comAnixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases $36,300.00 in StockAnixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) Director Arnold M. Baskies purchased 10,000 shares of the firm's stock in a transaction that occurred on Friday, March 15th. The stock was bought at an average price of $3.63 per share, with a total value of $36,300.00. Following the transaction, the director now directly owns 110,000 shares in the company, valued at $399,300. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.March 14, 2024 | prnewswire.comAnixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳 (Ad)45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open. Claim Exclusive 100% Bonus: $0.25/Share ANIX Media Mentions By Week ANIX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANIX News Sentiment▼0.030.55▲Average Medical News Sentiment ANIX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANIX Articles This Week▼32▲ANIX Articles Average Week Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Enzo Biochem News Psychemedics News Fate Therapeutics News Xeris Biopharma News Aquestive Therapeutics News Taysha Gene Therapies News Canopy Growth News Aura Biosciences News biote News Organogenesis News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANIX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.